FY2025 EPS Forecast for Edwards Lifesciences Cut by Analyst

Edwards Lifesciences Co. (NYSE:EW - Free Report) - Leerink Partnrs lowered their FY2025 earnings per share (EPS) estimates for Edwards Lifesciences in a research report issued on Wednesday, February 12th. Leerink Partnrs analyst M. Kratky now expects that the medical research company will post earnings per share of $2.41 for the year, down from their prior forecast of $2.43. The consensus estimate for Edwards Lifesciences' current full-year earnings is $2.56 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences' FY2026 earnings at $2.76 EPS and FY2027 earnings at $3.23 EPS.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%.

A number of other research analysts have also issued reports on the stock. Piper Sandler increased their target price on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 12th. Barclays raised their price objective on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an "overweight" rating in a research note on Thursday. Royal Bank of Canada reiterated an "outperform" rating and set a $85.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Robert W. Baird cut their target price on Edwards Lifesciences from $73.00 to $68.00 and set a "neutral" rating for the company in a research note on Friday, October 25th. Finally, JPMorgan Chase & Co. boosted their price target on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a "neutral" rating in a report on Friday, October 25th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences has an average rating of "Hold" and an average price target of $79.95.

Edwards Lifesciences Stock Performance

NYSE EW traded up $0.23 on Thursday, reaching $76.23. The stock had a trading volume of 3,899,190 shares, compared to its average volume of 4,438,355. Edwards Lifesciences has a 1-year low of $58.93 and a 1-year high of $96.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The firm has a fifty day moving average of $72.67 and a two-hundred day moving average of $69.58. The company has a market cap of $44.96 billion, a P/E ratio of 11.00, a price-to-earnings-growth ratio of 3.64 and a beta of 1.10.

Insider Activity

In other news, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $75.76, for a total transaction of $852,300.00. Following the completion of the transaction, the chief financial officer now directly owns 30,561 shares in the company, valued at $2,315,301.36. This trade represents a 26.91 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 2,500 shares of the company's stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $74.08, for a total transaction of $185,200.00. Following the completion of the sale, the vice president now owns 23,189 shares in the company, valued at $1,717,841.12. This represents a 9.73 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 26,489 shares of company stock worth $2,002,829 over the last quarter. 1.29% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Alpha Financial Partners LLC bought a new position in shares of Edwards Lifesciences during the 3rd quarter worth approximately $693,000. Koshinski Asset Management Inc. purchased a new stake in shares of Edwards Lifesciences during the third quarter valued at approximately $396,000. Vontobel Holding Ltd. lifted its holdings in Edwards Lifesciences by 5.7% during the third quarter. Vontobel Holding Ltd. now owns 439,106 shares of the medical research company's stock worth $28,977,000 after acquiring an additional 23,560 shares during the period. nVerses Capital LLC purchased a new position in Edwards Lifesciences in the third quarter worth $792,000. Finally, Trust Co. of Vermont grew its stake in Edwards Lifesciences by 36.1% in the 3rd quarter. Trust Co. of Vermont now owns 3,019 shares of the medical research company's stock valued at $199,000 after purchasing an additional 801 shares during the period. Hedge funds and other institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.